Crop Life Science Valuation
Is CLSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CLSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CLSL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CLSL's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLSL?
Other financial metrics that can be useful for relative valuation.
| What is CLSL's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹715.60m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does CLSL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.2x | ||
ARISTO Aristo Bio-Tech and Lifescience | 15.4x | n/a | ₹551.4m |
542123 Phosphate | 6.3x | n/a | ₹562.8m |
530883 Super Crop Safe | 25.7x | n/a | ₹562.2m |
524204 Teesta Agro Industries | 13.4x | n/a | ₹561.7m |
CLSL Crop Life Science | 15x | n/a | ₹715.6m |
Price-To-Earnings vs Peers: CLSL is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (15.2x).
Price to Earnings Ratio vs Industry
How does CLSL's PE Ratio compare vs other companies in the IN Chemicals Industry?
Price-To-Earnings vs Industry: CLSL is good value based on its Price-To-Earnings Ratio (15x) compared to the Indian Chemicals industry average (31.1x).
Price to Earnings Ratio vs Fair Ratio
What is CLSL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CLSL's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.